Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
Open Access
Abstract
We evaluated cellular immune responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in an immunized population based on HLA-E-restricted CD8+ T cell epitope identification. HLA-E-restricted SARS-CoV-2 CD8+ T cell nonamer peptides were predicted with software. An HLA-E-transfected K562 cell binding assay was used to screen for high-affinity peptides. IFN-γ enzyme-linked immunospot assays were used to identify HLA-E-restricted epitopes. An HLA-E/epitope tetramer was employed to detect the frequencies of epitope-specific CD8+ T cells. Four CD8+ T cell epitopes on the spike protein of SARS-CoV-2 restricted by both HLA-E*0101 and E*0103 were identified. HLA-E-restricted epitope-specific IFN-γ-secreting CD8+ T cell responses could be detected in individuals vaccinated with SARS-CoV-2 vaccines. Importantly, the frequencies of epitope-specific CD8+ T cells in Ad5-nCoV vaccinated individuals were higher than in individuals vaccinated with recombinant protein or inactivated vaccines. Moreover, the frequencies of epitope-specific CD8+ T cells could be maintained for at least 120 days after only one dose of Ad5-nCoV vaccine, while the frequencies of epitope-specific CD8+ T cells decreased in individuals after two doses of Ad5-nCoV vaccine. These findings may contribute to a more comprehensive evaluation of the protective effects of vaccines for SARS-CoV-2; meanwhile, they may provide information to characterize HLA-E-restricted CD8+ T cell immunity against SARS-CoV-2 infection.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82341071, 81871239, 2020SWAQ02, 2023-JC-ZD-49)
- Natural Science Foundation of Fourth Military Medical University, China (82341071, 81871239, 2020SWAQ02, 2023-JC-ZD-49)
- Key Projects of the Natural Science Basic Research Plan in Shaanxi Province, China (82341071, 81871239, 2020SWAQ02, 2023-JC-ZD-49)
This publication has 33 references indexed in Scilit:
- A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challengeNature Communications, 2020
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- Harnessing HLA‐E‐restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID‐19British Journal of Haematology, 2020
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialThe Lancet, 2020
- The unconventional role of HLA-E: The road less traveledMolecular Immunology, 2020
- Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19Nature Medicine, 2020
- HLA-E: exploiting pathogen-host interactions for vaccine developmentClinical and Experimental Immunology, 2019
- Characteristics of HLA-E Restricted T-Cell Responses and Their Role in Infectious DiseasesJournal of Immunology Research, 2016
- HLA-E: A Novel Player for HistocompatibilityJournal of Immunology Research, 2014